HBM HOLDINGS-B: Annual Report 2024

HKEXApr 22 10:13 ET · Announcements

Hong Kong stocks fluctuated | Pharmaceutical stocks generally declined as the Trump administration launched an investigation into pharmaceuticals, but Institutions remain Bullish on the growth potential of Innovative Drugs.

Pharmaceutical stocks generally fell. As of the time of writing, ASCLETIS-B (01672) dropped 12.64%, trading at 5.46 Hong Kong dollars; ALPHAMAB-B (09966) fell 7.74%, trading at 6.44 Hong Kong dollars; HBM HOLDINGS-B (02142) decreased by 7.31%, trading at 7.1 Hong Kong dollars.

Zhitong FinanceApr 15 23:24 ET

Hong Kong stocks have fluctuated | The Innovative Drugs Concept has seen significant gains. Institutions state that there is no need to pay tariffs on the licensing fees for Innovative Drugs, and support policies for Innovative Drugs are expected to be gr

The Innovative Drugs Concept has seen significant growth, as of the time of reporting, LAEKNA-B (02105) is up 13.16%, priced at 12.04 Hong Kong dollars; BRII-B (02137) is up 12.35%, priced at 1.82 Hong Kong dollars; CSTONE PHARMA-B (02616) is up 10.88%, priced at 2.65 Hong Kong dollars; BEIGENE (06160) is up 8.27%, priced at 148 Hong Kong dollars; HBM HOLDINGS-B (02142) is up 7.41%, priced at 7.68 Hong Kong dollars.

Zhitong FinanceApr 14 03:38 ET

Hong Kong stock market fluctuation | The Innovative Drugs Concept shows strong performance. Lepu Biotech-B (02157) rises over 18% and LAEKNA-B (02105) rises over 16%.

The Innovative Drugs Concept has shown strong performance. As of the time of writing, Lepu Biopharma-B (02157) is up 18.13%, trading at 4.3 Hong Kong dollars; LAEKNA-B (02105) is up 16.74%, trading at 10.88 Hong Kong dollars; AKESO (09926) is up 11.6%, trading at 82.75 Hong Kong dollars.

Zhitong FinanceApr 11 03:29 ET

Express News | Hbm Holdings - Intends to Repurchase Shares of Co in Open Market From Time to Time up to HK$200 Mln

ReutersApr 10 09:29 ET

Pharmaceutical stocks generally rose, WUXI XDC (02268) increased by 14.36%. According to Credit Lyonnais, the impact of tariff policies on Innovative Drugs is relatively small.

Jinwu Financial News | Pharmaceutical stocks mostly rose, WUXI XDC (02268) increased by 14.36%, VIVA BIOTECH (01873) rose by 12.3%, He_probe Pharmaceutical (02142) climbed by 11.37%, REMEGEN (09995) went up by 10.51%, WUXI BIO (02269) increased by 7.14%, and WUXI APPTEC (02359) rose by 5.89%. Credit Lyonnais published a research report indicating that due to the limited scale of China-U.S. pharmaceutical trade, the current expectation is that China's Medical Care Industry, especially in the Innovative Drugs sector, is relatively less affected by tariff policies, looking forward to optimization under centralized volume procurement and other policies.

Jingwu Financial NewsApr 9 22:41 ET